Journal: Scientific Reports

Article Title: GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy

doi: 10.1038/s41598-026-42195-7

Figure Lengend Snippet: Regulation of 4R tau level by GV1001 in vitro and in vivo. A Schematic diagram for the in vitro PSP neuronal model. SH-SY5Y cells were incubated in 1% FBS media containing retinoic acid (RA) and BDNF to optimize neuronal differentiation for six days. To induce 4R tauopathy, annonacin (0, 25, 50, and 100 nM) treatment was applied for 48 h. B 4R tau and total tau protein levels were analyzed using anti-4R tau antibody (RD4) and anti-total tau antibody (HT7), respectively. Original blot for 4R tau is presented in Supplementary data 12. Quantified graphs showing C 4R tau, D total tau, and E the ratio of 4R tau, with total tau obtained from three biological repeats. Data represent the mean and S.D. and analyzed using one-way ANOVA with Tukey’s multiple comparisons test; * p < 0.05 vs. 0 nM annonacin-treated cells. F GV1001 (1 µM) was post-treated for 24 h to the neuronal cells incubated with 25nM annonacin for 24 h. Quantified graphs for G 4R tau, H total tau, and I the ratio of 4R tau with total tau are presented with three biological repeats. Data represent the mean and S.D. and analysis was performed using one-way ANOVA with Tukey’s multiple comparisons test; * p < 0.05 vs. Ctrl group and # p < 0.05 vs. +Ann group. J Immunoblot analysis of whole brain lysates from TauP301L-BiFC mice administered with the vehicle, LMTM, or GV1001. Original blot for 4R tau is presented in Supplementary data 12. Quantified graphs for K mouse 4R tau, L mouse total tau, and M the ratio of 4R tau with total tau are presented. Data were analyzed using one-way analysis of variance with Tukey’s multiple comparisons test; * p < 0.05 compared with vehicle group.

Article Snippet: Anti-Tau (4-repeat isoform RD4) Antibody , N/A , Merck , 05–804.

Techniques: In Vitro, In Vivo, Incubation, Western Blot